Study of blood and renal Janus kinase 3 expression in pediatric systemic lupus erythematosus: a potential therapeutic target

stranded-DNA and SLEDAI and were significantly negatively correlated with serum complement 3 (p <0.000). Renal JAK 3 expression was significantly positively correlated with 24-hour urinary proteins and urinary RBCs (p<0.000). Conclusion: The increased JAK 3 expression among pSLE patients and its strong association with validated parameters of SLE activity could make it a potential therapeutic target for pSLE patients especially those with LN.

• Publication year

  2025

• Venue

  The Egyptian Journal of Pediatric Allergy and Immunology

• Publication date

  2025-10-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.21608/ejpa.2025.429473.1092
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).

  2023cited by this paper
• OP0053 EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL

  2023cited by this paper
• Correlation between peripheral blood lymphocyte subpopulations and primary systemic lupus erythematosus

  2022cited by this paper
• Therapeutic Effects of Tofacitinib on Pristane-Induced Murine Lupus

  2022cited by this paper
• Oral tofacitinib citrate for recalcitrant cutaneous lupus

  2021cited by this paper
• Baricitinib for recalcitrant subacute cutaneous lupus erythematosus with concomitant frontal fibrosing alopecia

  2021cited by this paper
• Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus

  2021cited by this paper
• Abnormalities of the type I interferon signaling pathway in lupus autoimmunity.

  2021cited by this paper
• Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus

  2021cited by this paper
• Treatment of refractory subacute cuataneous lupus erythematosus with baricitinib

  2021cited by this paper
• Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib

  2021cited by this paper
• JAK/STAT signaling controls the fate of CD8+CD103+ tissue-resident memory T cell in lupus nephritis.

  2020cited by this paper
• Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy

  2020cited by this paper
• Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation

  2019cited by this paper
• JAK2 and PTPRC mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus

  2019cited by this paper
• Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.

  2018cited by this paper
• The role of neutrophil extracellular traps in rheumatic diseases

  2018cited by this paper
• Clinical relevance of circulating anti‐ENA and anti‐dsDNA secreting cells from SLE patients and their dependence on STAT‐3 activation

  2017cited by this paper
• JAK3-STAT pathway blocking benefits in experimental lupus nephritis

  2016cited by this paper
• Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.

  2012cited by this paper
• Depletion of Autoreactive Plasma Cells and Treatment of Lupus Nephritis in Mice Using CEP-33779, a Novel, Orally Active, Selective Inhibitor of JAK2

  2011cited by this paper
• Clinical tests: sensitivity and specificity

  2008cited by this paper

• No citing papers are available for this paper.